Last reviewed · How we verify
Ribavirin in Arm 1
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools.
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools. Used for Chronic hepatitis C (in combination with interferon or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.
At a glance
| Generic name | Ribavirin in Arm 1 |
|---|---|
| Sponsor | MinaPharm Pharmaceuticals |
| Drug class | Nucleoside analog antiviral |
| Target | Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase) |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ribavirin is a guanosine analog that gets phosphorylated intracellularly and incorporated into viral RNA, causing chain termination and mutations. It also inhibits inosine monophosphate dehydrogenase (IMPDH), reducing guanosine nucleotide availability needed for viral replication. This dual mechanism makes it effective against a broad spectrum of RNA viruses.
Approved indications
- Chronic hepatitis C (in combination with interferon or direct-acting antivirals)
- Severe respiratory syncytial virus (RSV) infection
- Hemorrhagic fever with renal syndrome
- Lassa fever
Common side effects
- Hemolytic anemia
- Teratogenicity/embryocidal effects
- Fatigue
- Headache
- Dyspnea
- Nausea
- Insomnia
- Depression/mood changes
Key clinical trials
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF (PHASE2)
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (PHASE2)
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ribavirin in Arm 1 CI brief — competitive landscape report
- Ribavirin in Arm 1 updates RSS · CI watch RSS
- MinaPharm Pharmaceuticals portfolio CI